--- a
+++ b/clusters/9knumclustersv2/clust_1491.txt
@@ -0,0 +1,20 @@
+Previous treatment with ixazomib or pomalidomide
+Previous treatment with ixazomib, or participation in a study with ixazomib whether treated with ixazomib or not
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not
+Myeloma disease that is refractory to ixazomib treatment
+Known hypersensitivity to bortezomib, ixazomib, dexamethasone, or ONC
+Prior treatment with ixazomib
+Inability to take ixazomib or abatacept
+Patients that have previously been treated with daratumumab or ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not
+Previously treated with ixazomib (excluding comparator or placebo participants not on current treatment with ixazomib) in a Millennium-sponsored study. Participants will be eligible to enter the rollover study when:
+The participant is on ixazomib monotherapy or on a drug combination with another medication, established while in his/her parent study; and
+Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib
+Patients that have previously been treated with ixazomib, or who participated in a blinded study with ixazomib (whether treated with ixazomib or not)
+Previous treatment with ixazomib, or participated in a blinded study with ixazomib
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not; (NOTE: prior ibrutinib treatment is allowed as per: patients with prior exposure to ibrutinib will be allowed if they do not have disease refractory to ibrutinib; patient receiving ibrutinib will be allowed on this trial if they have measurable disease and did not have disease progression while receiving ibrutinib; prior bortezomib treatment is allowed as per: patients with prior exposure to bortezomib will be allowed if they do not have disease refractory to bortezomib)
+Prior participation in a randomized controlled study that included MLN (ixazomib) in one of the treatment arms independent of whether assigned to MLN (ixazomib) or not
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not
+Previous use of interferon, ixazomib or bortezomib
+Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not